Antibodies targeting modified citrullinated vimentin in patients with psoriatic arthritis (CROSBI ID 553323)
Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Tešija-Kuna, Andrea ; Miler, Marijana ; Grazio, Simeon ; Grubišić, Frane ; Vukasović, Ines ; Perić, Porin
engleski
Antibodies targeting modified citrullinated vimentin in patients with psoriatic arthritis
Background: Recently it has been found that antibodies against modified citrullinated vimentin (anti-MCV) have comparable performance in diagnosis of rheumatoid arthritis (RA) as the antibodies targeting citrullinated peptides (anti- CCP). While anti-CCP is present in up to 15% of psoriatic arthritis (PsA) patients, the prevalence of anti-MCV in PsA patients has been poorly investigated. Our objective was to determine the prevalence and significance of anti MCV antibodies in patients with PsA. Methods: The study included 56 patients with PsA (29 male, 27 female, mean age 57± ; 12 years). Clinical features, disease activity and functional ability were noted by experienced rheumatologist. Serum samples of all patients were analyzed for anti-MCV antibodies using commercially available ELISA (Orgentec Diagnostika). Anti-CCP antibodies with ELISA (Euroimmun) and RF with latex immunoturbidimetry were also determined in all patients. Results: Anti-MCV antibodies were positive in 2/56 (3.6%) PsA patients. In one patient anti-MCV level was medium/high while in other borderline. Both patients had asymmetric polyarthritis, dactylitis and were anti-CCP and RF negative. five clinical types of PsA. No correlation between anti-MCV levels and disease activity variables or results of Health Assessment Questionnaire (HAQ) was found. Anti-CCP antibodies were negative in all patients. Conclusions: According to our findings the anti-MCV antibodies can be detected in a small proportion of PsA patients. Although the presence of anti-MCV in these patients with polyarthritic disease could presume psoriasis with concomitant RA, most of the clinical characteristics favor PsA as the primary diagnosis.
rheumatoid arthritis ; citrullinated vimentin ; psoriatic arthritis
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
S117-S117.
2009.
nije evidentirano
objavljeno
Podaci o matičnoj publikaciji
Clinical chemistry and laboratory medicine. Special supplement
Siest, Gerard
Berlin: Walter de Gruyter
1437-8523
Podaci o skupu
18th IFCC-EFCC European Congress of Clinical Chemistry and Laboratory Medicine
poster
07.06.2009-11.06.2009
Innsbruck, Austrija